- Fujifilm’s forecasted operating income for the fiscal year is 331.00 billion yen, slightly below the estimated 336.76 billion yen.
- The company expects net income to reach 262.00 billion yen, surpassing the estimate of 259.56 billion yen.
- Projected net sales are 3.28 trillion yen, exceeding the estimated 3.26 trillion yen.
- The anticipated dividend is 70.00 yen, higher than the estimate of 64.11 yen.
- In the fourth quarter, Fujifilm reported operating income of 106.88 billion yen, above the estimate of 91.2 billion yen.
- Net income for the fourth quarter was 79.41 billion yen, beating the estimated 65.32 billion yen.
- Fourth quarter net sales were 868.31 billion yen, compared to the estimate of 840.34 billion yen.
- Annual operating income amounted to 330.16 billion yen, higher than the estimated 316.27 billion yen.
- Annual net income reached 260.95 billion yen, surpassing the estimate of 247.95 billion yen.
- The company achieved annual net sales of 3.20 trillion yen, above the estimated 3.15 trillion yen.
- R&D expenses were 163.40 billion yen, slightly less than the estimate of 165.87 billion yen.
- Analyst ratings include 12 buys, 5 holds, and no sells.
FUJIFILM Holdings on Smartkarma
On Smartkarma, independent analysts like Shifara Samsudeen, FCMA, CGMA, provide insights into FUJIFILM Holdings. In a bullish report titled “Fujifilm: Bio CDMO – A Success in the Making,” it is highlighted that Fujifilm has secured a $3 billion manufacturing deal with Regeneron Pharma. This success stems from Fujifilm’s Bio CDMO business, specifically FUJIFILM Diosynth Biotechnologies, which has shown significant growth and success through strategic investments and acquisitions. The business aims to achieve revenues of ¥200 billion by FY03/2025 and ¥500 billion by FY03/2028E.
Another positive outlook comes from the Tech Supply Chain Tracker, which reports on “Tech Supply Chain Tracker (05-Dec-2024): AI sovereignty.” This bullish report mentions that artificial intelligence has been granted sovereign status, with Fujifilm Taiwan expanding its operations by building a new plant in Hsinchu. The report also touches on strong results from Marvell in 3Q24 due to high demand for AI silicon. These insights from top independent analysts offer a glimpse into the growth and potential opportunities in FUJIFILM Holdings.
A look at FUJIFILM Holdings Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have provided an overall outlook score for FUJIFILM Holdings Corporation, a company that develops, sells, and services Imaging, Information, and Document Solutions. The company has received a solid score of 4 for its Value, indicating strong potential in terms of its valuation compared to competitors. Additionally, its Dividend, Growth, Resilience, and Momentum scores all fall in the mid-range from 3 to 3, highlighting steady performance across these key factors.
Considering the scores provided by Smartkarma, FUJIFILM Holdings appears to showcase promising prospects in terms of its value proposition, with decent performance in other important aspects such as dividend yield, growth potential, resilience in challenging market conditions, and momentum in the market. Investors may find this balanced outlook appealing for long-term investment considerations.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
